Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients

The protein therapeutic and CD95L inhibitor asunercept is currently under clinical investigation for the treatment of glioblastoma and myelodysplastic syndrome. The purpose of this study was to predict the asunercept pharmacokinetics in children and to give dose recommendations for its first use in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanke, Nina, Kunz, Claudia, Thiemann, Meinolf, Fricke, Harald, Lehr, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523206/
https://www.ncbi.nlm.nih.gov/pubmed/30939793
http://dx.doi.org/10.3390/pharmaceutics11040152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523206/
https://www.ncbi.nlm.nih.gov/pubmed/30939793
http://dx.doi.org/10.3390/pharmaceutics11040152

Ejemplares similares